Development and preliminary validation of the Adolescent Psoriasis Quality of Life instrument (APso-QOL): a disease-specific measure of quality of life in adolescents with psoriasis.

No age-appropriate and disease-specific instrument currently exists to measure health-related quality of life (HRQOL) in adolescents with psoriasis (12-17 years).To develop and provide preliminary validation of the Adolescent Psoriasis Quality […]

» Read more

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.

Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline addresses important clinical questions that arise in psoriasis management […]

» Read more

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS).

Guselkumab, a fully human interleukin-23 antibody, is approved for systemic treatment of patients with moderate-to-severe plaque psoriasis.To compare efficacy and safety of guselkumab with fumaric acid esters (FAE) in systemic […]

» Read more
1 2 3 4